Wall Street Analysts Are Bullish on Top Healthcare Picks

view original post

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Agilent (AResearch Report), Intellia Therapeutics (NTLAResearch Report) and BioMarin Pharmaceutical (BMRNResearch Report) with bullish sentiments.

Agilent (A)

In a report issued on February 21, Puneet Souda from Leerink Partners maintained a Buy rating on Agilent. The company’s shares closed last Friday at $132.03.

According to TipRanks.com, Souda ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -7.8% and a 41.2% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Agilent has an analyst consensus of Moderate Buy, with a price target consensus of $140.17.

See Insiders’ Hot Stocks on TipRanks >>

Intellia Therapeutics (NTLA)

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics on February 22. The company’s shares closed last Friday at $26.10, close to its 52-week low of $22.67.

According to TipRanks.com, Foroohar is a 1-star analyst with an average return of -0.9% and a 46.8% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, 4D Molecular Therapeutics, and Lexeo Therapeutics, Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Intellia Therapeutics with a $62.57 average price target, a 134.2% upside from current levels. In a report issued on February 15, Canaccord Genuity also maintained a Buy rating on the stock with a $72.00 price target.

BioMarin Pharmaceutical (BMRN)

Leerink Partners analyst Joseph Schwartz reiterated a Buy rating on BioMarin Pharmaceutical on February 22 and set a price target of $126.00. The company’s shares closed last Friday at $91.24.

According to TipRanks.com, Schwartz is a 4-star analyst with an average return of 2.9% and a 43.5% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceutical.

Currently, the analyst consensus on BioMarin Pharmaceutical is a Moderate Buy with an average price target of $107.28, a 18.0% upside from current levels. In a report issued on February 16, Jefferies also maintained a Buy rating on the stock with a $133.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on A: